Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer

Robert J. Amato, Cherie Perez, Lance Pagliaro

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalInvestigational New Drugs
Issue number4
StatePublished - Nov 2002


  • Irofulven
  • Kidney cancer
  • Phase II
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer'. Together they form a unique fingerprint.

Cite this